Brief: Bridgebio Pharma Inc Issues $632.5 Million Convertible Senior Notes Due 2033
21/01/2026 21:32
Jan 21 (Reuters) - BridgeBio Pharma Inc BBIO.O: BRIDGEBIO PHARMA INC - ISSUES $632.5 MILLION CONVERTIBLE SENIOR NOTES DUE 2033 - SEC FILING BRIDGEBIO PHARMA INC - TO USE PROCEEDS FOR REPURCHASE OR REPAYMENT OF 2027 NOTES - SEC FILING BRIDGEBIO PHARMA INC - RECEIVES $619.3 MILLION NET PROCEEDS FROM NOTE OFFERING - SEC FILING Source text: [ID:n0001140361-26-001843] Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels